Margaret Georgiadis
Co-founder and CEO @ Montai Therapeutics
San Francisco, United States
Margaret Georgiadis is a seed investor at Montai Therapeutics in San Francisco focused on Health Care and Apps. Margaret Georgiadis is based out of Cambridge, Massachusetts and is the Co-founder and CEO of Montai Therapeutics. Margaret previously worked at Ancestry as a President and CEO. Margaret Georgiadis attended Harvard Business School. Margaret Georgiadis has received the Excellence Award in Innovation.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Margaret Georgiadis invests in
Stages Margaret Georgiadis invests in
Countries Margaret Georgiadis invests in
Round sizes
Round size
- Seed
- $2.3M–$5.8M
- Series A
- $11M–$50M
- Series B
- $20M–$24M
Investment Focus
Industry
- Health Care 6 (40%)
- Apps 2 (13%)
- Medical 2 (13%)
- Women's 2 (13%)
- Software 2 (13%)
Stage
- Seed 7 (47%)
- Series A 4 (27%)
- Series B 2 (13%)
- Pre-Seed 1 (7%)
Country
- United States 12 (80%)
- United Kingdom 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Evvy
|
Evvy is a developer of at-home vaginal microbiome tests to close the gender health gap and improve female health. It uses metagenomic sequencing to understand symptoms and risks for critical health challenges, and get personalized reports. | $14M / Series A / Sep 27, 2023 | |
ShareWell
|
ShareWell is a peer assistance platform that allows users to participate in small group video sessions. The company was founded in 2021 and is headquartered in San Francisco, California. | $1.3M / Pre-Seed / Feb 16, 2023 | |
OneRoof
|
OneRoof connects people living in the same building to form a resourceful, fun, and supportive neighbor community. The company was founded in 2020 and is headquartered in Brooklyn, New York. | $3.2M / Seed / Jan 05, 2023 | |
Montai Therapeutics
|
Montai Health platform enables rapid and repeatable advancement of therapies across multiple diseases. | $50M / Series A / Dec 13, 2022 | |
Bridge Money
|
Bridge is a seed stage fintech startup, built to empower members to make more money. | $5.8M / Seed / Sep 28, 2022 | |
Lisa Health
|
Midday is a digital platform for menopause and midlife women's health. Menopause is a transition every woman around the globe will experience. Eighty-five percent will have symptoms that adversely impact their health, quality of life, relationships, and productivity at work. Lisa Health manages the menopause journey and midlife wellbeing withpersonalized, science-based, community-supported guidance. | $2.5M / Seed / Jul 22, 2022 | |
TaskHuman
|
Amplify your work and personal life with 1:1 personalized guidance from LIVE specialists over video calls. Instantly discover and connect with the world’s most comprehensive global network of coaches, instructors, and specialists covering nearly 1000 aspects of your daily life, such as physical fitness, mental well-being, spiritual, emotional,financial, life & leadership coaching, and more. We’ve scoured the globe to find, curate, and bring you a diverse network of specialists 24/7 right to your fingertips. Enjoy 100% secure and confidential 1:1 sessions on the TaskHuman platform anytime, anywhere. Whether you want to work out 1:1 with a kickboxing coach, get support on your career goals from a leadership coach, or simply get help for managing your favorite pet - now you can experience a human connection like never before. Build your personalized dream team of human specialists to help you with your life! With our revolutionary pricing model, get free calls with every coach until you find the best fit for your personality and goals. Then buy and use TaskHuman minutes and engage ANY coach in the network for the same rate. Take the time to put yourself first with TaskHuman! | $20M / Series B / Jun 21, 2022 | |
Sano Genetics
|
Sano Genetics is a health technology company that focuses on personalized medicine and genetics. They aim to empower individuals to contribute their genetic and health data for research purposes, with the goal of advancing scientific understanding and personalized approaches to healthcare. Sano Genetics often operates within the context of geneticresearch studies and projects, allowing participants to share their genetic information to contribute to the broader field of medical research | $11M / Series A / Mar 28, 2022 | |
GoodTrust
|
GoodTrust is a secure digital legacy platform for your websites, social media, online accounts and documents with easy share function now or when you pass away. | $5M / Seed / Dec 20, 2021 | |
Let's Enhance
|
Let's Enhance is a deep-tech company that builds next-gen AI photo management solution for marketplaces | $3M / Seed / Oct 27, 2021 | |
| See all 15 investments → | |||
Co-Investors
About Montai Therapeutics
Montai Health platform enables rapid and repeatable advancement of therapies across multiple diseases.
Montai Therapeutics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Margaret Georgiadis
Co-founder and CEO
|
|||
Margaret Georgiadis
Co-founder and CEO
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Margaret Georgiadis invest in?
Margaret Georgiadis invests primarily in Health Care, Apps and Medical startups, most often at Seed and Series A stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Margaret Georgiadis's check size?
Margaret Georgiadis typically joins rounds of $2.3M–$5.8M at Seed, $11M–$50M at Series A and $20M–$24M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Margaret Georgiadis participates in.
When did Margaret Georgiadis last invest?
The most recent investment recorded for Margaret Georgiadis closed in Sep 2023. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
